

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM589509

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	RELEASE OF SECURITY INTEREST		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
BPCR Limited Partnership		07/30/2020	Limited Partnership: ENGLAND
RECEIVING PARTY DATA			
Name:	Amicus Therapeutics, Inc.		
Street Address:	1 Cedar Brook Drive		
City:	Cranbury		
State/Country:	NEW JERSEY		
Postal Code:	08512		
Entity Type:	Corporation: DELAWARE		
PROPERTY NUMBERS Total: 5			
Property Type	Number	Word Mark	
Registration Number:	5541266	GALAFOLD	
Serial Number:	86839457	GALAFOLD	
Serial Number:	86839465		
Serial Number:	86839473	GALAFOLD	
Serial Number:	86839478		
CORRESPONDENCE DATA			
Fax Number:	6175269899		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	6175269628		
Email:	cslattery@proskauer.com		
Correspondent Name:	Christine Slattery		
Address Line 1:	Proskauer Rose LLP		
Address Line 2:	One International Place, 23rd Floor		
Address Line 4:	Boston, MASSACHUSETTS 02110		
ATTORNEY DOCKET NUMBER:	33858 / 008		
NAME OF SUBMITTER:	Christine Slattery		
SIGNATURE:	/Christine Slattery/		
DATE SIGNED:	07/30/2020		

CH \$140.00 5541266

Total Attachments: 4

source=Amicus Termination and Release of Security Interest in Intellectual Property TMSA#page1.tif

source=Amicus Termination and Release of Security Interest in Intellectual Property TMSA#page2.tif

source=Amicus Termination and Release of Security Interest in Intellectual Property TMSA#page3.tif

source=Amicus Termination and Release of Security Interest in Intellectual Property TMSA#page4.tif

**TERMINATION AND RELEASE OF SECURITY INTEREST
IN TRADEMARK COLLATERAL**

This Termination and Release of Security Interest in Trademark Collateral (this "Release") is made this 30th day of July, 2020, by BPCR Limited Partnership, a limited partnership formed under the laws of England with an address of c/o Beaufort House, 51 New North Road, Exeter, United Kingdom EX4 4EP, as successor to BioPharma Credit PLC, on behalf of itself and the other Secured Parties (as defined in the Loan Agreement referred to below) ("Lender"), in favor of Amicus Therapeutics, Inc., a Delaware corporation, (the "Grantor").

WHEREAS, among others, the Grantor and Lender entered into (i) that certain Loan Agreement dated as of September 19, 2018 (as may be amended, restated, supplemented or otherwise modified from time to time, the "Loan Agreement"), and (ii) that certain Guaranty and Security Agreement dated as of September 28, 2018 (as may be amended, restated, supplemented or otherwise modified from time to time, the "Security Agreement" and together with the Loan Agreement, the "Loan Documents").

WHEREAS, in connection with the Loan Documents and pursuant to the terms and conditions of that certain Trademark Security Agreement entered into by the Grantor in favor of Lender, for the benefit of itself and the other Secured Parties, dated as of September 28, 2018 (the "Trademark Security Agreement"), the Grantor granted to Lender, for the benefit of itself and the other Secured Parties, a continuing security interest in, to and under the Trademark Collateral (as defined in the Trademark Security Agreement), including the trademarks set forth on Schedule A hereto (the "Trademarks");

WHEREAS, the Trademark Security Agreement was recorded with the United States Patent and Trademark Office ("USPTO") on September 28, 2018 at Reel/Frame 6472/0887;

WHEREAS, the interest in the Trademarks as set forth in the Trademark Security Agreement was confirmed in that certain Omnibus Confirmation of Assignment Agreement dated as of May 21, 2020, as recorded with the USPTO on May 21, 2020 at Reel/Frame 6944/0430;

WHEREAS, the Grantor's obligations under the Loan Agreement and Security Agreement have been satisfied in full and the security interest granted to Lender has been released by Lender;

WHEREAS, Lender has the requisite power and authority to release and discharge its security interest in, to and under the Trademark Collateral; and

WHEREAS, the parties desire to confirm and evidence the termination and release of the security interest in, to and under the Trademark Collateral.

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Lender, on behalf of itself and its successors,

legal representatives and assigns, hereby unconditionally, irrevocably and absolutely (i) assigns to the Grantor all of Lender's right, title and interest (if any) in, to and under the Trademark Collateral, including the Trademarks and (ii) terminates, cancels, releases and forever discharges any and all security interests it holds in, to and under the Trademark Collateral, including the Trademarks.

Lender shall take all further reasonable actions, and provide to the Grantor or its successors, assigns or other legal representatives, all such reasonable cooperation and assistance (including, without limitation, the execution and delivery of any and all documents or other instruments), requested by the Grantor to more fully and effectively effectuate the purposes of this Release, in each case, at the Grantor's expense. By this instrument, Lender authorizes and requests that the Grantor record this Release with the USPTO.

REMAINDER OF PAGE INTENTIONALLY LEFT BLANK


SIGNATURE PAGE FOLLOWS

IN WITNESS WHEREOF, Lender has caused this Release to be executed by its respective duly authorized representative as of the date first above written.

BPCR LIMITED PARTNERSHIP





By: Pharmakon Advisors, LP, its Investment
Manager

By: Pharmakon Management I, LLC, its
General Partner

By: 
Name: Pedro Gonzalez de Cosio
Title: Managing Member

SCHEDULE A

TRADEMARK REGISTRATIONS

Amicus No.	LS No.	Country	Image Title	Trademark	Status	Application No.	Application Date	Registration No.	Registration Date	Class/Goods
North America GAL-4BE-US	3114732	United States		GALAFOLD	Registered	89/465,401	11/26/2014	5,541,266	8/14/2018	Class 5: Pharmaceutical preparations for the treatment of Fabry disease
GAL-3BE-US	3114743	United States		GALAFOLD & Design (No Color Claim - Black & White)	Allowed	89/839,457	12/4/2015			Class 5: Pharmaceutical preparations for the treatment of Fabry disease
GAL-2BE-US	3114744	United States		Galafold Design Logo (No Color Claim - Black & White)	Allowed	86/839,465	12/4/2015			Class 5: Pharmaceutical preparations for the treatment of Fabry disease
GAL-3OE-US	3114745	United States		GALAFOLD & Design (Color Claim)	Allowed	89/839,473	12/4/2015			Class 5: Pharmaceutical preparations for the treatment of Fabry disease
GAL-2OE-US	3114746	United States		Galafold Design Logo (Color Claim)	Allowed	86/839,479	12/4/2015			Class 5: Pharmaceutical preparations for the treatment of Fabry disease